95884-09-6

Basic information

• Product Name: 3H-Pyrazol-3-one, 5-phenyl-
• CAS NO: 95884-09-6
• Molecular Formula: C9H6N2O
• Molecular Weight: 158.159
• Mol File: 95884-09-6.mol

Chemical Properties

• CAS DataBase Reference: 3H-Pyrazol-3-one, 5-phenyl-(CAS DataBase Reference)
• NIST Chemistry Reference: 3H-Pyrazol-3-one, 5-phenyl-(95884-09-6)
• EPA Substance Registry System: 3H-Pyrazol-3-one, 5-phenyl-(95884-09-6)

Safety Data

• Hazardous Substances Data: 95884-09-6(Hazardous Substances Data)

Upstream product

• 1846-74-8 3-benzoyl-chromen-2-one 
• 54441-63-3 propyl 3-oxo-3-phenylpropanoate 

Downstream Products

• 104044-40-8 6-(5-phenyl-3-pyrazolyloxy)hexyl alcohol 
• 1268837-56-4 5-[(5-oxo-3-phenyl-4,5-dihydro-1H-pyrazol-4-yl)diazenyl]-1,3-diphenyl-1H-pyrazole-4-carbaldehyde 

Relevant articles and documents

Conversions of coumarins accompanied by intermediate opening and recyclization of the lactone ring. 2. Study of the interaction of malonic acid hydrazide and amide derivatives with 3-acyl(3-cyano, 3-ethoxycarbonyl)coumarins

Reaction between the N,N′-diisopropylidene and N,N′-diacetyl derivatives of malonic acid dihydrazide and 3-acyl(3-cyano, 3-ethoxycarbonyl) coumarins under the conditions of the Michael reaction lead to the formation of N′-isopropylidene and N′-acetyl derivatives of coumarin-3-carboxylic acid hydrazide. Ethoxycarbonylacethydrazide reacts in an analogous manner. Special features have been studied of the interaction of malonic acid amide derivatives with unsubstituted coumarin and with coumarins containing electron-withdrawing groupings in position 3 of the ring. 2005 Springer Science+Business Media, Inc.

PYRAZOLYL SUBSTITUTED CARBONIC ACID DERIVATIVES AS MODULATORS OF THE PROSTACYCLIN(PGI2) RECEPTOR USEFUL FOR THE TREATMENT OF DISORDERS RELATED THERETO

Pyrazole derivatives of Formula Ia and pharmaceutical compositions thereof that modulate the activity of the PGI2 receptor. Compounds of the present invention and pharmaceutical compositions thereof are directed to methods useful in the treatment of: pulmonary arterial hypertension (PAH) and related disorders; platelet aggregation; coronary artery disease; myocardial infarction; transient ischemic attack; angina; stroke; ischemia-reperfusion injury; restenosis; atrial fibrillation; blood clot formation in an angioplasty or coronary bypass surgery individual or in an individual suffering from atrial fibrillation; atherosclerosis; atherothrombosis; asthma or a symptom thereof; a diabetic-related disorder such as diabetic peripheral neuropathy, diabetic nephropathy or diabetic retinopathy; glaucoma or other disease of the eye with abnormal intraocular pressure; hypertension; inflammation; psoriasis; psoriatic arthritis; rheumatoid arthritis; Crohn's disease; transplant rejection; multiple sclerosis; systemic lupus erythematosus (SLE); ulcerative colitis; ischemia-reperfusion injury; restenosis; atherosclerosis; acne; type 1 diabetes; type 2 diabetes; sepsis; and chronic obstructive pulmonary disorder (COPD).